On December 13th, Greatwall Enterprise Institute released its "GEI China Potential Unicorn Enterprises Report 2025". Leveraging cutting-edge innovation and outstanding commercialization capabilities in the field of synthetic biology, Leadsynbio was successfully selected for the list, demonstrating our strong growth potential and core competitiveness. 

As a "Potential Unicorn Enterprise," Leadsynbio is characterized by advanced technological sophistication, presence in emerging industry segments, and significant growth prospects. Such enterprises play an important role in driving frontier technological innovation, fostering development momentum, and enhancing competitive advantages.

This recognition vividly reflects our integration into the growth of national strategic scientific and technological strength. Since the establishment in 2015,we have built two major R&D centers in China and the United States, along with modern production bases in Hunan and Anhui, establishing an integrated supply chain from R&D to production. Currently, over ten core raw materials, including the Florfenicol, NMN/NAD, 25-Hydroxy Vitamin D₃, and pharmaceutical intermediates, have achieved stable, large-scale supply and are exported to more than twenty countries and regions worldwide. Our market share has risen rapidly, positioning us among the industry leaders.

Looking ahead, Leadsynbio will continue to deepen technological innovation and strengthen industrial chain collaboration, accelerating the R&D and commercialization of new products. We are committed to becoming an industry leader, contributing lasting momentum into the high-quality development of the bioeconomy and human health.